NASDAQ:MEIPMEI Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MEI Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.85 +0.07 (+2.52 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$2.71Now: $2.85▼$2.8550-Day Range$2.59MA: $3.54▼$4.3052-Week Range$0.72Now: $2.85▼$4.46Volume834,477 shsAverage Volume1.55 million shsMarket Capitalization$302.10 millionP/E RatioN/ADividend YieldN/ABeta1.78 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, MEI Pharma has a potential upside of 286.0% from its current price of $2.85.Amount of Analyst CoverageMEI Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesMEI Pharma has received 346 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMEI Pharma has received 272 “underperform” votes. (Add your “underperform” vote.)Community SentimentMEI Pharma has received 55.99% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote “Outperform” if you believe MEIP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.77% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions66.83% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to decrease in the coming year, from ($0.06) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -9.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -9.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone858-369-7100Debt Debt-to-Equity RatioN/A Current Ratio9.30 Quick Ratio9.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.91 million Price / Sales61.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book4.25Profitability EPS (Most Recent Fiscal Year)($0.62) Net Income$-16,820,000.00 Net Margins-539.48% Return on Equity-60.32% Return on Assets-41.93%Miscellaneous Employees32 Outstanding Shares106,000,000Market Cap$302.10 million Next Earnings Date8/26/2020 (Estimated) OptionableOptionable $2.85 +0.07 (+2.52 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MEIP News and Ratings via Email Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions How has MEI Pharma's stock been impacted by COVID-19 (Coronavirus)? MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MEIP stock has increased by 83.9% and is now trading at $2.85. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of MEI Pharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MEI Pharma. When is MEI Pharma's next earnings date? MEI Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for MEI Pharma. How were MEI Pharma's earnings last quarter? MEI Pharma Inc (NASDAQ:MEIP) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.09. The firm had revenue of $1.24 million for the quarter, compared to analyst estimates of $1.28 million. MEI Pharma had a negative net margin of 539.48% and a negative return on equity of 60.32%. View MEI Pharma's earnings history. What price target have analysts set for MEIP? 4 equities research analysts have issued twelve-month price targets for MEI Pharma's shares. Their forecasts range from $9.00 to $13.00. On average, they anticipate MEI Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 286.0% from the stock's current price. View analysts' price targets for MEI Pharma. Has MEI Pharma been receiving favorable news coverage? Press coverage about MEIP stock has trended somewhat negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEI Pharma earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news about MEI Pharma. Who are some of MEI Pharma's key competitors? Some companies that are related to MEI Pharma include Karyopharm Therapeutics (KPTI), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Constellation Pharmaceuticals (CNST), Akcea Therapeutics (AKCA), Nabriva Therapeutics (NBRV), Arcturus Therapeutics (ARCT), Esperion Therapeutics (ESPR), I-Mab (ARQT), Akero Therapeutics (AKRO), Humanigen (HGEN), VBI Vaccines (VBIV), Phathom Pharmaceuticals (PHAT), Phibro Animal Health (PAHC) and DiaMedica Therapeutics (DMCAF). View all competitors. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Opko Health (OPK), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX). Who are MEI Pharma's key executives? MEI Pharma's management team includes the following people: Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)Mr. David A. Walsey, VP of IR & Corp. Communications What is MEI Pharma's stock symbol? MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP." Who are MEI Pharma's major shareholders? MEI Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.48%), Strategic Wealth Advisors Group LLC (0.10%), Strs Ohio (0.07%), SG Americas Securities LLC (0.05%), UBS Group AG (0.03%) and Hancock Whitney Corp (0.03%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View institutional ownership trends for MEI Pharma. Which institutional investors are selling MEI Pharma stock? MEIP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for MEI Pharma. Which institutional investors are buying MEI Pharma stock? MEIP stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Strategic Wealth Advisors Group LLC, Strs Ohio, Hancock Whitney Corp, SG Americas Securities LLC, Diversified Trust Co, and ProShare Advisors LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, and Thomas C Reynolds. View insider buying and selling activity for MEI Pharma. How do I buy shares of MEI Pharma? Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MEI Pharma's stock price today? One share of MEIP stock can currently be purchased for approximately $2.85. How big of a company is MEI Pharma? MEI Pharma has a market capitalization of $302.10 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe. What is MEI Pharma's official website? The official website for MEI Pharma is www.meipharma.com. How can I contact MEI Pharma? MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected] This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
